Company profile
ARDELYX, INC.
NASDAQ:ARDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBSRELA | approved | $86.2MQ2 2026 | 3 | approved |
| XPHOZAH | approved | $31.9MQ2 2026 | 3 | approved |
| TENAPANOR | phase4 | — | 22 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06553547 | phase2 | completed | 2024-07-24 | 2026-07-07 | Ardelyx | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
| NCT02621892 | phase3 | completed | 2015-10-01 | 2017-03-01 | Ardelyx | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C |
| NCT02686138 | phase3 | completed | 2015-12-01 | 2017-08-01 | Ardelyx | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C |
| NCT07382167 | phase3 | recruiting | 2026-01-13 | 2027-02-26 | Ardelyx | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults |
| NCT02727751 | phase3 | completed | 2016-03-01 | 2017-10-01 | Ardelyx | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 213931 | 2023-10-17 | NDA | ARDELYX INC | |||||
Loading… | ||||||||
| NDA 211801 | 2019-09-12 | NDA | ARDELYX INC | |||||
Loading… | ||||||||